Arnaud Butzbach

CEO & Co-Founder @neocustic C-Level Exec & Entrepreneur: Innovation / R&D / Operations / IT / Life Sciences / Medical

📍 Biot, Provence-Alpes-Cote d'Azur, France🔄 Updated September 2026💼 2 investments📅 9 years investing🗓 Last invested Sep 2018
Operator-angel🌍 France
2
Total investments
2
Early stage
0
Mid stage
0
Late stage
9y
Years active

Portfolio

2 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Independent Board Member
Sep 2018
BIOSENCY is a medical device company focused on developing smart healthcare solutions. Our first product, a connected PPG sensor system using smart data is a monitoring and prevention solution dedicated to respiratory insufficiency. Our company is based in Rennes, France. We work closely with doctors and researchers to bring to the medical community the best possible tools to help patients.
Independent Board Member
Jun 2017
VitaDX develops software solutions to detect cancer using image processing and artificial intelligence. For more information check out our website: www.vitadx.com Follow us on twitter @VitaDX_SA
early stageMedical Device
Experience · 5 entries
All (5)
Investments (2)
Founder (3)
Board (2)
2018
Independent Board Member
Sep 2018
BIOSENCY is a medical device company focused on developing smart healthcare solutions. Our first product, a connected PPG sensor system using smart data is a monitoring and prevention solution dedicated to respiratory insufficiency. Our company is based in Rennes, France. We work closely with doctors and researchers to bring to the medical community the best possible tools to help patients.
CEO & Co-Founder
Aug 2018
neocustis is a newly established MedTech Start up that offers personalized hearing solutions through remote services for hearing loss assessment, fitting and re-education. Combining connected hearing aid technology with smart software services, we will improve the treatment of hearing disorders. Our hearing solutions leverage your very own data (patient, environment, usage data) and personalized artificial intelligence, altogether enabling richer life experience, across all generations. We keep people communicating, and eventually, we help augment human capabilities.
early stageMedical Device
2017
Independent Board Member
Jun 2017
VitaDX develops software solutions to detect cancer using image processing and artificial intelligence. For more information check out our website: www.vitadx.com Follow us on twitter @VitaDX_SA
early stageMedical Device
2010
Co-founder, Vice-President Operations & Chief Technology Officer
Apr 2010
Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone. We harness the power of medical images by using the most advanced Artificial Intelligence technologies, to increase the accuracy of diagnosis and treatment of many cancers and other metabolic diseases at their earliest stages and provide insights into novel therapies for patients. Our iCRO solutions for medical image analysis and management in oncology trials and eyonis™, our AI/ML tech-based suite of software as medical devices (SaMD) help biopharmaceutical companies and clinicians to bring new treatments and diagnose patients earlier and more accurately. This is how we are helping to create a healthier world. Founded in 2002, based in Sophia-Antipolis, France, with a subsidiary in the US and another one in Shanghai, Median has received the label “Innovative company” by the BPI and is listed on Euronext Growth market (Paris). FR0011049824– ticker: ALMDT. Median is eligible for the French SME equity savings plan scheme (PEA-PME).
2003
Co-founder, Chief Technology Officer, Head of Corporate Services
Jun 2003
Median Technologies provides innovative imaging solutions and services to advance healthcare for everyone. We harness the power of medical images by using the most advanced Artificial Intelligence technologies, to increase the accuracy of diagnosis and treatment of many cancers and other metabolic diseases at their earliest stages and provide insights into novel therapies for patients. Our iCRO solutions for medical image analysis and management in oncology trials and eyonis™, our AI/ML tech-based suite of software as medical devices (SaMD) help biopharmaceutical companies and clinicians to bring new treatments and diagnose patients earlier and more accurately. This is how we are helping to create a healthier world. Founded in 2002, based in Sophia-Antipolis, France, with a subsidiary in the US and another one in Shanghai, Median has received the label “Innovative company” by the BPI and is listed on Euronext Growth market (Paris). FR0011049824– ticker: ALMDT. Median is eligible for the French SME equity savings plan scheme (PEA-PME).